How does iRemedy respond to such supply chain bottlenecks?

As seen during the COVID pandemic, the U.S. has long relied on foreign manufacturers for essential medical products, making us vulnerable to hold-ups in the supply chain. How does iRemedy respond to such supply chain bottlenecks??

While we have been able to improve our supply chain, it is still far from where we want it to be. The unfortunate answer is that iRemedy has no choice but to accept the reality that most of our inventory originates in Asia. Whether we buy from a prominent distributor in the US or a manufacturer overseas, the grim reality is that there is essentially zero medical manufacturing in the US – and this was especially true prior to the pandemic.

This began to change in March of 2020 and we are seeing more medical manufacturers come online in the US than ever, but is primarily for COVID-related supplies and built on faulty COVID economics. There are a few companies who have obsessed over becoming highly efficient, automated manufacturers in the US and we believe those companies can sustain. But for the time being, we are forced to accept the fact that these supply chain bottlenecks cannot be fixed overnight.